A Systematic Study of the Hepatic–Intestinal First-Pass Effect and Excretion Pathways of Punicalagin Based on UPLC-MS/MS
Molecules · 2026
DOI: 10.3390/molecules31030393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Zixin Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Xinjiang Medical University, Urumqi 830017, China. Hauptthemen laut MEDLINE: Hydrolyzable Tannins, Liver, Intestinal Mucosa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Major Special Fund Support Projects of Xinjiang Uygur Autonomous Region, Natural Science Foundation of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Punicalagin, the major polyphenol in pomegranate peel, shows broad bioactivity but suffers from poor oral bioavailability. Whether hepatic or intestinal first-pass processes dominate this limitation remains unresolved. We developed a quantitative UPLC-MS/MS workflow to dissect punicalagin’s first-pass disposition and elimination in rats. Sprague–Dawley rats received punicalagin by intravenous, portal vein, oral, or intraduodenal dosing; plasma exposure was quantified by UPLC-MS/MS and analyzed noncompartmentally. We also profiled urinary and fecal excretion of punicalagin and key metabolites (punicalin, ellagic acid, urolithin C and urolithin A) to define biotransformation and clearance. Punicalagin displayed an absolute oral bioavailability of ~3.49%. First-pass analysis revealed modest hepatic extraction (~13.94%) but near-complete intestinal extraction (95.95%), identifying intestinal first-pass metabolism as the dominant barrier to systemic exposure. Consistently, parent and metabolites were eliminated mainly in feces, whereas urine contained only trace conjugated urolithin A. Collectively, these findings demonstrate that the poor oral bioavailability of punicalagin is driven primarily by extensive intestinal first-pass metabolism rather than hepatic clearance, and that its feces-dominant elimination is compatible with widespread hydrolysis and microbiota-mediated conversion within the gut. This work provides a pharmacokinetic framework to guide strategies aimed at improving oral delivery and systemic exposure of punicalagin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Xinjiang Medical University, Urumqi 830017, China.
- Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, Urumqi 830011, China.
Förderung
- National Natural Science Foundation of China
- Major Special Fund Support Projects of Xinjiang Uygur Autonomous Region
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
Zitieren
APA
Chen, Z., Chang, Z., Yao, P., & Gao, X. (2026). A Systematic Study of the Hepatic–Intestinal First-Pass Effect and Excretion Pathways of Punicalagin Based on UPLC-MS/MS. Molecules. https://doi.org/10.3390/molecules31030393
Vancouver
Chen Z, Chang Z, Yao P, Gao X. A Systematic Study of the Hepatic–Intestinal First-Pass Effect and Excretion Pathways of Punicalagin Based on UPLC-MS/MS. Molecules. 2026. doi:10.3390/molecules31030393
BibTeX
@article{Chen2026,
author = {Chen, Zixin and Chang, Zhanying and Yao, Pengxia and Gao, Xiaoli},
title = {A Systematic Study of the Hepatic–Intestinal First-Pass Effect and Excretion Pathways of Punicalagin Based on UPLC-MS/MS},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31030393}
}
EUVIMED